Expand CORT Menu
CORT MENU

CORT Stock Posts


Unusual Option Volume

CORT Corcept Therapeutics71.87-3.15 (-4.2%)

Corcept Therapeutics trades 2,992 contracts. The company has the following event: on Dec 17, 2026.
View Details...
Unusual Option Volume

CORT Corcept Therapeutics74.65+1.88 (+2.6%)

Corcept Therapeutics trades 4,609 contracts. The company has the following event: on Dec 17, 2026.
View Details...
Unusual Option Volume

CORT Corcept Therapeutics72.55+0.92 (+1.3%)

Corcept Therapeutics trades 3,131 contracts. The highest volume is in the 15-Jan-27 55 puts.
View Details...
CORT #CorceptTherapeutics stock declines -3.0% in after hours trading. See the latest news.

After Hours Decliner

CORT Corcept Therapeutics81.93+1.47+1.8%

After Hours:79.50-2.43 (-3.0%)

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

Business WireTue, 3-Nov 4:05 PM
Upcoming Earnings

CORT Corcept Therapeutics82.75+2.29 (+2.9%)

Corcept Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±13.4% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±11.6%. View Expected Move (Conf Call: Nov 3 5:00 PM)
Unusual Option Volume

CORT Corcept Therapeutics87.14+1.28 (+1.5%)

Corcept Therapeutics trades 6,724 contracts. The company has the following event: on Dec 17, 2026. News: Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
View Details...
Load Earlier Posts
Market Data Delayed 15 Minutes